pidilizumab formerly monoclonal antibody developed medivation treatment cancer infectious pidilizumab originally thought bind immune checkpoint molecule however recent evidence suggests deltalike primary binding target binding secondary restricted nonglycosylated hypoglycosylated forms pidilizumab causes attenuation apoptotic processes lymphocytes primarily effectormemory cells encouraging results phase ii clinical trials diffuse large bcell phase ii openlabel study combination relapsed follicular lymphoma found good results compared usual response rates phase iii open label study pediatric patients rare form brain cancer diffuse intrinsic pontine glioma found improvement overall survival compared expected outcomecitation needed addon trial multiple myeloma immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding httpsenwikipediaorgwikipidilizumab